Nurix Therapeutics Inc. Company Profile
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics at a glance
Nurix Therapeutics Inc. (NASDAQ: NRIX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Brisbane, CA. Nurix Therapeutics is led by Dr. Arthur T. Sands M.D., Ph.D. and employs about 317 people. The company's shares have traded publicly since 2020.
At a market capitalization of $1.40 billion, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001549595, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Nurix Therapeutics do?
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Business description based on the company's public filings.
Company information
- Legal name
- Nurix Therapeutics Inc.
- Ticker
- NASDAQ: NRIX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Arthur T. Sands M.D., Ph.D.
- Employees
- 317
- Headquarters
- 1600 Sierra Point Parkway, Brisbane, CA, United States
- Phone
- 415 660 5320
- Website
- nurixtx.com
- IPO year
- 2020
- Market cap
- $1.40B
- SEC CIK
- 0001549595
Companies similar to Nurix Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs NRIX |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs NRIX |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs NRIX |
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs NRIX |
| KLRAKailera Therapeutics Inc. | 11.02 | -4.84% | $1.43B | vs NRIX |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs NRIX |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs NRIX |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs NRIX |